Dualitas Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$65M
- Investors
-
7
Dualitas Therapeutics General Information
Description
Developer of a bispecific antibody therapeutics platform designed for addressing immunology and inflammation. The company's platform integrates discovery and rapid candidate optimization to identify novel bispecific antibody candidates by functionally screening the entire cell surface, enabling patients with immune and inflammatory diseases to access therapies with the potential for greater pharmacologic activity and more meaningful clinical benefit.
Contact Information
Website
www.dualitastx.comCorporate Office
- 259 East Grand Avenue
- Suite 504
- South San Francisco, CA 94080
- United States
Corporate Office
- 259 East Grand Avenue
- Suite 504
- South San Francisco, CA 94080
- United States
Dualitas Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 16-Sep-2025 | $65M | Completed | Startup |
Dualitas Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Dualitas Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Dualitas Therapeutics Patents
Dualitas Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025226194-A1 | Bispecific screening compositions and methods | Pending | 23-Feb-2024 | ||
| WO-2025179145-A1 | Bispecific screening compositions and methods | Pending | 23-Feb-2024 | ||
| WO-2025179145-A9 | Bispecific screening compositions and methods | Pending | 23-Feb-2024 | C12N9/2462 |
Dualitas Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Dualitas Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Chugai Venture Fund | Corporate Venture Capital | Minority | ||
| Lilly USA | Corporation | Minority | ||
| Qiming Venture Partners | Venture Capital | Minority | ||
| Qiming Venture Partners USA | Venture Capital | Minority |
Dualitas Therapeutics FAQs
-
When was Dualitas Therapeutics founded?
Dualitas Therapeutics was founded in 2023.
-
Where is Dualitas Therapeutics headquartered?
Dualitas Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Dualitas Therapeutics?
Dualitas Therapeutics has 25 total employees.
-
What industry is Dualitas Therapeutics in?
Dualitas Therapeutics’s primary industry is Drug Discovery.
-
Is Dualitas Therapeutics a private or public company?
Dualitas Therapeutics is a Private company.
-
What is the current valuation of Dualitas Therapeutics?
The current valuation of Dualitas Therapeutics is .
-
What is Dualitas Therapeutics’s current revenue?
The current revenue for Dualitas Therapeutics is .
-
How much funding has Dualitas Therapeutics raised over time?
Dualitas Therapeutics has raised $65M.
-
Who are Dualitas Therapeutics’s investors?
Alexandria Venture Investments, Chugai Venture Fund, Lilly USA, Qiming Venture Partners, and Qiming Venture Partners USA are 5 of 7 investors who have invested in Dualitas Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
